Alcohol and the mechanisms of liver disease.
alcoholic liver disease
ethanol metabolism
gut microbiota
immunity
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
13
06
2023
received:
23
05
2023
accepted:
14
06
2023
medline:
31
8
2023
pubmed:
10
7
2023
entrez:
9
7
2023
Statut:
ppublish
Résumé
Alcoholic liver disease (ALD), which is a leading cause of morbidity and mortality worldwide, covers a large spectrum of liver injuries ranging from simple steatosis to steatohepatitis, advanced fibrosis, cirrhosis, and hepatocellular carcinoma. The pathogenesis of ALD includes genetic and epigenetic alterations, oxidative stress, acetaldehyde-mediated toxicity and cytokine and chemokine-induced inflammation, metabolic reprogramming, immune damage, and dysbiosis of the gut microbiota. This review discusses the progress in the pathogenesis and molecular mechanism of ALD, which could provide evidence for further research on the potential therapeutic strategies targeting these pathways.
Substances chimiques
Ethanol
3K9958V90M
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233-1240Subventions
Organisme : National Natural Science Foundation of China
ID : 81902907
Organisme : National Natural Science Foundation of China
ID : M-0334
Organisme : Shanghai Pujiang Program
ID : 2019PJD008
Organisme : Shenkang - Three-year Clinical Research Foundation
ID : SHDC2020CR3031B
Organisme : Key Project of Xuhui District Municipal Health Commission
ID : XHLHGG202103
Informations de copyright
© 2023 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Kraut JA, Mullins ME. Toxic alcohols. N. Engl. J. Med. 2018; 378: 270-280.
Simon L, Souza-Smith FM, Molina PE. Alcohol-associated tissue injury: current views on pathophysiological mechanisms. Annu. Rev. Physiol. 2022; 84: 87-112.
Wu X, Fan X, Miyata T et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease. Annu. Rev. Pathol. Mech. Dis. 2023; 18: 411-438.
Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 2021; 326: 165.
Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2023; 20: 37-49.
Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J. Hepatol. 2019; 70: 284-293.
Hendriks HFJ. Alcohol and human health: what is the evidence? Ann. Rev. Food Sci. Technol. 2020; 11: 1-21.
Becker U, Deis A, Sorensen TI et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025-1029.
Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin. Liver Dis. 2012; 16: 659-666.
Bellentani S, Saccoccio G, Costa G et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997; 41: 845-850.
Buch S, Stickel F, Trépo E et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat. Genet. 2015; 47: 1443-1448.
Mancina RM, Ferri F, Farcomeni A et al. A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption. Appl. Clin. Genet. 2019; 12: 1-10.
Yang J, Trépo E, Nahon P et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int. J. Cancer 2019; 144: 533-544.
Joshi-Barve S, Kirpich I, Cave MC, Marsano LS, McClain CJ. Alcoholic, nonalcoholic, and toxicant-associated steatohepatitis: mechanistic similarities and differences. Cell. Mol. Gastroenterol. Hepatol. 2015; 1: 356-367.
Kirpich I, Ghare S, Zhang J et al. Binge alcohol-induced microvesicular liver steatosis and injury are associated with down-regulation of hepatic Hdac1, 7, 9, 10, 11 and up-regulation of Hdac3. Alcohol. Clin. Exp. Res. 2012; 36: 1578-1586.
Verma AK, Sharma A, Subramaniyam N, Gandhi CR. Augmenter of liver regeneration: mitochondrial function and steatohepatitis. J. Hepatol. 2022; 77: 1410-1421.
Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 2018; 155: 629-647.
Han D, Johnson HS, Rao MP et al. Mitochondrial remodeling in the liver following chronic alcohol feeding to rats. Free Radic. Biol. Med. 2017; 102: 100-110.
Holbrook OT, Molligoda B, Bushell KN, Gobrogge KL. Behavioral consequences of the downstream products of ethanol metabolism involved in alcohol use disorder. Neurosci. Biobehav. Rev. 2022; 133: 104501.
Willems PHGM, Rossignol R, Dieteren CEJ, Murphy MP, Koopman WJH. Redox homeostasis and mitochondrial dynamics. Cell Metab. 2015; 22: 207-218.
Yan T, Zhao Y. Acetaldehyde induces phosphorylation of dynamin-related protein 1 and mitochondrial dysfunction via elevating intracellular ROS and Ca2+ levels. Redox Biol. 2020; 28: 101381.
Guerrero-Castillo S, Baertling F, Kownatzki D et al. The assembly pathway of mitochondrial respiratory chain complex I. Cell Metab. 2017; 25: 128-139.
Samuvel DJ, Li L, Krishnasamy Y et al. Mitochondrial depolarization after acute ethanol treatment drives mitophagy in living mice. Autophagy 2022; 18: 2671-2685.
Hodson L, Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. Nat. Rev. Endocrinol. 2019; 15: 689-700.
Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology 2020; 158: 1899-1912.
Thomes PG, Rasineni K, Yang L et al. Ethanol withdrawal mitigates fatty liver by normalizing lipid catabolism. Am. J. Physiol.-Gastrointest. Liver Physiol. 2019; 316: G509-G518.
Le TNH, Choi HJ, Jun HS. Ethanol extract of Liriope platyphylla root attenuates non-alcoholic fatty liver disease in high-fat diet-induced obese mice via regulation of lipogenesis and lipid uptake. Nutrients 2021; 13: 3338.
He Z, Guo T, Cui Z et al. New understanding of Angelica sinensis polysaccharide improving fatty liver: the dual inhibition of lipid synthesis and CD36-mediated lipid uptake and the regulation of alcohol metabolism. Int. J. Biol. Macromol. 2022; 207: 813-825.
Zhang K, Kim H, Fu Z et al. Deficiency of the mitochondrial NAD kinase causes stress-induced hepatic steatosis in mice. Gastroenterology 2018; 154: 224-237.
Luginbühl M, Stöth F, Schröck A, Gaugler S, Weinmann W. Quantitative determination of phosphatidylethanol in dried blood spots for monitoring alcohol abstinence. Nat. Protoc. 2021; 16: 283-308.
Marmier S, Dentin R, Daujat-Chavanieu M et al. Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking. Hepatology 2015; 62: 1086-1100.
Lee HI, Yun KW, Seo KI, Kim MJ, Lee MK. Scopoletin prevents alcohol-induced hepatic lipid accumulation by modulating the AMPK-SREBP pathway in diet-induced obese mice. Metabolism 2014; 63: 593-601.
Luo P, Zheng M, Zhang R et al. S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling. Acta Pharm. Sin. B. 2021; 11: 668-679.
Yang YM, Cho YE, Hwang S. Crosstalk between oxidative stress and inflammatory liver injury in the pathogenesis of alcoholic liver disease. Int. J. Mol. Sci. 2022; 23: 774.
Sasaki-Tanaka R, Ray R, Moriyama M, Ray RB, Kanda T. Molecular changes in relation to alcohol consumption and hepatocellular carcinoma. Int. J. Mol. Sci. 2022; 23: 9679.
Malherbe DC, Messaoudi I. Transcriptional and epigenetic regulation of monocyte and macrophage dysfunction by chronic alcohol consumption. Front. Immunol. 2022; 13: 911951.
Ma HY, Yamamoto G, Xu J et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J. Hepatol. 2020; 72: 946-959.
Lee J, Shim Y, Seo W et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through toll-like receptor 3 in alcohol-associated liver injury. Hepatology 2020; 72: 609-625.
Verma VK, Li H, Wang R et al. Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J. Hepatol. 2016; 64: 651-660.
Jeong W, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-γ contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008; 134: 248-258.
Cui K, Yan G, Zheng X et al. Suppression of natural killer cell activity by regulatory NKT10 cells aggravates alcoholic hepatosteatosis. Front. Immunol. 2017; 8: 1414.
Yi HS, Lee YS, Byun JS et al. Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice. Hepatology 2014; 60: 1044-1053.
Gieseck RL, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat. Rev. Immunol. 2018; 18: 62-76.
Ghare S, Patil M, Hote P et al. Ethanol inhibits lipid Raft-mediated TCR signaling and IL-2 expression: potential mechanism of alcohol-induced immune suppression. Alcohol. Clin. Exp. Res. 2011; 35.
Gao Y, Zhou Z, Ren T et al. Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids. Gut 2019; 68: 1311-1322.
Ambade A, Lowe P, Kodys K et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology 2019; 69: 1105-1121.
McTernan PM, Levitt DE, Welsh DA, Simon L, Siggins RW, Molina PE. Alcohol impairs immunometabolism and promotes naïve T cell differentiation to pro-inflammatory Th1 CD4+ T cells. Front. Immunol. 2022; 13: 839390.
Hoxhaj G, Ben-Sahra I, Lockwood SE et al. Direct stimulation of NADP + synthesis through Akt-mediated phosphorylation of NAD kinase. Science 2019; 363: 1088-1092.
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol. 2020; 72: 558-577.
Gao B, Ahmad MF, Nagy LE, Tsukamoto H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 2019; 70: 249-259.
Luo P, Wang F, Wong NK et al. Divergent roles of Kupffer cell TLR2/3 signaling in alcoholic liver disease and the protective role of EGCG. Cell. Mol. Gastroenterol. Hepatol. 2020; 9: 145-160.
Kawaratani H, Moriya K, Namisaki T et al. Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (review). Int. J. Mol. Med. 2017; 40: 263-270.
Shim YR, Jeong WI. Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease. Exp. Mol. Med. 2020; 52: 772-780.
Fujii C, Zorumski CF, Izumi Y. Ethanol, neurosteroids and cellular stress responses: Impact on central nervous system toxicity, inflammation and autophagy. Neurosci. Biobehav. Rev. 2021; 124: 168-178.
Xu MJ, Cai Y, Wang H et al. Fat-specific protein 27/CIDEC promotes development of alcoholic steatohepatitis in mice and humans. Gastroenterology 2015; 149: 1030-1041.e6.
Liu W, Vetreno RP, Crews FT. Hippocampal TNF-death receptors, caspase cell death cascades, and IL-8 in alcohol use disorder. Mol. Psychiatry 2021; 26: 2254-2262.
Song Q, Chen Y, Wang J et al. ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development. J. Hepatol. 2020; 73: 783-793.
Szuster-Ciesielska A, Mizerska-Dudka M, Daniluk J, Kandefer-Szerszeń M. Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress. J. Gastroenterol. 2013; 48: 222-237.
Page A, Paoli PP, Hill SJ et al. Alcohol directly stimulates epigenetic modifications in hepatic stellate cells. J. Hepatol. 2015; 62: 388-397.
Torres JL, Novo-Veleiro I, Manzanedo L et al. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J. Gastroenterol. 2018; 24: 4104-4118.
Segal ZV, Bieling P, Young T et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch. Gen. Psychiatry 2010; 67: 1256.
Bjørkhaug ST, Aanes H, Neupane SP et al. Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut Microbes. 2019; 10: 663-675.
Llopis M, Cassard AM, Wrzosek L et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016; 65: 830-839.
Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair. 2010; 3: 21.
Leclercq S, Matamoros S, Cani PD et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl. Acad. Sci. 2014; 111. https://doi.org/10.1073/pnas.1415174111
Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int. 2012; 32: 467-475.
Kirpich IA, Solovieva NV, Leikhter SN et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-682.
Mookerjee RP, Stadlbauer V, Lidder S et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46: 831-840.
Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Off. J. Am. Coll. Gastroenterol. ACG. 2001; 96: 1251.
Bass NM, Neff G, Frederick T, Shaw A. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 2010; 362: 1071-1081.
Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol. Clin. North Am. 2012; 41: 781-803.
Tian Z, Liu J, Liao M et al. Beneficial effects of fecal microbiota transplantation on ulcerative colitis in mice. Dig. Dis. Sci. 2016; 61: 2262-2271.
Ianiro G, Bibbò S, Gasbarrini A, Cammarota G. Therapeutic modulation of gut microbiota: current clinical applications and future perspectives. Curr. Drug Targets 2014; 15: 762-770.
Konturek PC, Haziri D, Brzozowski T et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2015; 66: 483-491.
Thursz M, Gual A, Lackner C et al. EASL clinical practice guidelines: management of alcohol-related liver disease. J. Hepatol. 2018; 69: 154-181.
Simonetto DA, Shah VH, Kamath PS. Outpatient management of alcohol-related liver disease. Lancet Gastroenterol. Hepatol. 2020; 5: 485-493.
Im GY. Primed for the spotlight: transplantation for alcohol-associated liver disease. J. Hepatol. 2018; 69: 253-254.
Krestinina O, Odinokova I, Sotnikova L, Krestinin R, Zvyagina A, Baburina Y. Astaxanthin is able to prevent alcohol-induced dysfunction of liver mitochondria. Antioxidants. 2022; 11: 2019.
Morley KC, Baillie A, Van Den Brink W et al. N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. Expert Opin. Investig. Drugs 2018; 27: 667-675.
Zhao X, Wang C, Dai S et al. Quercetin protects ethanol-induced hepatocyte pyroptosis via scavenging mitochondrial ROS and promoting PGC-1α-regulated mitochondrial homeostasis in L02 cells. Oxid. Med. Cell. Longev. 2022; 2022: 1-15.
Zhang H, Xue L, Li B, Zhang Z, Tao S. Vitamin D protects against alcohol-induced liver cell injury within an NRF2-ALDH2 feedback loop. Mol. Nutr. Food Res. 2019; 63: 1801014.
Tao Z, Zhang L, Wu T, Fang X, Zhao L. Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARα. Food Chem. Toxicol. 2021; 148: 111956.
Xu L, Zhang X, Xin Y et al. Depdc5 deficiency exacerbates alcohol-induced hepatic steatosis via suppression of PPARα pathway. Cell Death Dis. 2021; 12: 710.